Quantum BioPharma announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial of its dietary supplement product unbuzzd, investigating its effects on alcohol intoxication and alcohol metabolism. Key findings from the clinical trial include: Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication. Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Five new option listings and option delistings on January 21st
- Quantum BioPharma Closes Third Tranche Offering with Amended Terms
- Quantum BioPharma Advances Legal Actions Against Former CEO
- Quantum BioPharma to be in court with Raza Bokhari on January 24
- Quantum BioPharma Expands Global Reach with Upstream Listing